Discover OmniSource®

Full service and support so patients can get on—and stay on—therapy quickly and efficiently

As access becomes a more complex challenge for growth hormone therapy, it can be more challenging to help patients get on—and stay on—treatment. OmniSource is committed to giving healthcare professionals the support they need to get their patients on therapy quickly and efficiently.

OmniSource offerings

Here are some other things you and your patients can expect from OmniSource once enrolled:

  • OmniSource Clinical Nurse Educator (CNE) Onboarding

    An OmniSource CNE will work with your patients to provide personalized services throughout the onboarding process

  • Statement of Medical Necessity (SMN)

    Complete, download, and print the form here >

  • eConsent Form

    To help us get your patients started, they can electronically authorize the release of personal health information, which will help facilitate the onboarding process when signing up for OmniSource. Complete the form here >

  • Patient Authorization Form

    Complete, download, and print the form here >

  • Nurse Trainers and Injection Training

    If “Injection Training” is selected on the SMN, a Nurse Trainer provided by OmniSource will visit your patient’s home to give instruction on how to properly administer Omnitrope. Phone and video training options are also available

  • Dedicated Nurse Hotline

    To ask trained nurses nonmedical questions about Omnitrope, call us Monday - Friday, 8AM – 8PM ET at 877.456.6794

  • OmniSource e-Prescribing Platform

    A simple and streamlined platform to support providers prescribing Omnitrope. Register here >

  • Updated Sandoz OmniStart (SOS) Interim Drug Program

    If requested on the SMN, eligible patients will receive their medication and injection device within 10 business days of qualifying for SOS, so they don’t have to delay their treatment while waiting for insurance approvals*

To begin the onboarding process, have your patient complete our electronic consent form

*SOS is available for a maximum of twelve (12) months to commercially insured patients with an FDA-approved Omnitrope indication during first-time benefits investigation and

expired prior authorizations. SOS is also available for a maximum of two (2) months to government-insured patients with an FDA-approved Omnitrope indication during first-time benefits investigation only. This program is not health insurance. Product dispensed under SOS is not eligible for claim reimbursement and should not be submitted to any third-party private payer. SOS does not require, nor will be made contingent on, purchase requirements of any kind. Sandoz reserves the right to amend, rescind, or discontinue this program at any time without further notice. Additional eligibility criteria may apply. Contact OmniSource for further details.

*SOS is available for a maximum of twelve (12)

months to commercially insured patients with an FDA-approved Omnitrope indication during first-time benefits investigation and expired prior authorizations. SOS is also available for a maximum of two (2) months to government-insured patients with an FDA-approved Omnitrope indication during first-time benefits investigation only. This program is not health insurance. Product dispensed under SOS is not eligible for claim reimbursement and should not be submitted to any third-party private payer. SOS does not require, nor will be made contingent on, purchase requirements of any kind. Sandoz reserves the right to amend, rescind, or discontinue this program at any time without further notice. Additional eligibility criteria may apply. Contact OmniSource for further details.

Omnitrope Co-Pay Savings Program Eligibility

The Omnitrope Co-Pay Savings Program provides up to $5,000 in annual co-pay support for Omnitrope prescriptions. With the Omnitrope Co-Pay Savings Program, eligible patients may pay $0 for their co-pay. Eligible patients who are commercially insured may receive co-pay support in the amount of up to $5,000 annually and patients who are uninsured may receive co-pay support in the amount of up to $417 monthly, with an annual cap of $5,000. Prescription must be for an approved indication. This program is not health insurance. Patients are not eligible if prescriptions are paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TriCare, or private indemnity, or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law. Patients can participate for a maximum of 12 months. Eligible patients must have a first use of the program by December 31 of the current year. Omnitrope Co-Pay Savings Program may not be combined with any other rebate, coupon, or offer. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

INDICATIONS

Omnitrope is a recombinant human growth hormone indicated for:

  • Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi Syndrome, Small for Gestational Age, Turner Syndrome, and Idiopathic Short Stature
  • Adult: Treatment of adults with either adult onset or childhood onset GHD

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • Acute Critical Illness: Somatropin should not be used to treat patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure
  • Prader-Willi Syndrome in Children: Somatropin should not be used in patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients
  • Active Malignancy: Somatropin is contraindicated in patients with any evidence of active malignancy. Growth hormone deficiency may be an early sign of a pituitary tumor or other intracranial tumor; the presence of such a tumor should be excluded before initiation of somatropin treatment
  • Hypersensitivity: Omnitrope® is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients. Systemic hypersensitivity reactions have been reported with postmarketing use of somatropin products
  • Diabetic Retinopathy: Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy
  • Closed Epiphyses: Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses

WARNINGS AND PRECAUTIONS

  • Acute Critical Illness: Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic doses of somatropin
  • Prader-Willi Syndrome in Children: There have been reports of fatalities after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Patients with Prader-Willi syndrome should be evaluated for signs of upper airway obstruction and sleep apnea before initiation of treatment with somatropin. If, during treatment with somatropin, patients show signs of upper airway obstruction (including onset of or increased snoring) and/or new onset sleep apnea, treatment should be interrupted
  • Neoplasms: An increased risk of a second neoplasm has been reported for childhood cancer survivors treated with somatropin for GH deficiency that developed following radiation to the brain/head. Intracranial tumors, in particular meningiomas, were the most common of these. The relationship between somatropin therapy and CNS tumor recurrence in adults is unknown. Monitor for progression or recurrence in patients receiving somatropin therapy who have a history of GH deficiency secondary to an intracranial neoplasm. Thoroughly consider the risks and benefits of starting somatropin in children at increased risk for developing malignancies due to certain rare genetic causes of short stature. These patients should be carefully monitored for development of neoplasms. Any pre-existing nevi should be monitored carefully for increased growth or potential malignant changes
  • Impaired Glucose Intolerance and Diabetes Mellitus: Previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be unmasked during somatropin treatment. New-onset type 2 diabetes mellitus has been reported. As a result, blood glucose concentrations should be monitored periodically in all patients taking somatropin, especially in those with risk factors for diabetes mellitus. Patients with pre-existing type 1 or type 2 diabetes mellitus or impaired glucose tolerance should be monitored closely during somatropin treatment

Show more....